S. Ziti-Ljajic

发表

Translational Model‐Based Strategy to Guide the Choice of Clinical Doses for Antibody–Drug Conjugates

C. Nicolazzi, C. Veyrat‐Follet, M. Bouillon-Pichault, 2017, Journal of clinical pharmacology.

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours

P. Fumoleau, N. Isambert, V. Trillet-lenoir, 2012, British Journal of Cancer.

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

P. Fumoleau, N. Isambert, V. Trillet-lenoir, 2012, Clinical Cancer Research.

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

R. Houot, B. Coiffier, H. Tilly, 2013, Clinical Cancer Research.

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

S. Jagannath, D. Siegel, Chiung-Yu Huang, 2021, Cancer.

A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations

Jianming Xu, R. Xu, N. Le bail, 2017, Investigational New Drugs.

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

W. Mason, J. Machiels, B. Melichar, 2022, ESMO open.

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

M. Jongen‐Lavrencic, A. Wei, S. de Botton, 2022, Blood.

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

E. Oki, N. Sugimoto, D. Sakai, 2019, Cancer science.

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

P. Richardson, N. Raje, S. Usmani, 2017 .

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

P. Fumoleau, N. Isambert, G. Freyer, 2012, Clinical Cancer Research.

A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).

A. Tolcher, K. Papadopoulos, V. Moreno, 2016 .